LCTX · Lineage Cell Therapeutics Inc
United States · RS rating 10 · As of 2026-10-14
| Price | 0.92 USD |
|---|---|
| 1-day change | +0.8% |
| RS rating (overall / 1M / 3M / 12M) | 10 / 18 / 18 / 15 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 29 / 13 / 31 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | +79.5% |
| Distance from 52-week high | +53.2% |
| Market cap (USD) | $388.6M |